Table 1.
Demographic and clinical characteristics of the subjects with different vascular risk factor (VRF) burdens who provided serum samples.
| Characteristic | Low-risk group (n = 24) | Medium-risk group (n = 27) | High-risk group (n = 14) | F or χ2 | P-value |
|---|---|---|---|---|---|
| Sex | |||||
| Malea [N, (%)] | 9 (13.85) | 19 (29.23) | 13 (20.00) | 12.69 | <0.01 |
| Femalea [N, (%)] | 15 (23.08) | 8 (12.31) | 1 (1.54) | 12.69 | <0.01 |
| Agea ( ± s, years) | 58.54 ± 5.48 | 65.59 ± 6.51 | 72.57 ± 5.76 | 25.00 | <0.01 |
| Education ( ± s, years) | 9.13 ± 2.88 | 7.93 ± 2.29 | 10.21 ± 3.02 | 3.55 | <0.05 |
| Hypertensiona [N, (%)] | 4 (6.15) | 16 (24.62) | 10 (15.38) | 13.86 | <0.01 |
| DMa [N, (%)] | 0 (0.00) | 3 (4.62) | 4 (6.15) | 7.52 | <0.05 |
| CVDa [N, (%)] | 1 (1.54) | 2 (3.08) | 6 (9.23) | 12.70 | <0.01 |
| AFa [N, (%)] | 0 (0.00) | 0 (0.00) | 4 (6.15) | 15.53 | <0.01 |
| Current Smokinga [N, (%)] | 0 (0.00) | 8 (12.31) | 4 (6.15) | 8.62 | <0.05 |
| LVHa [N, (%)] | 1 (1.54) | 0 (0.00) | 0 (0.00) | 1.74 | 0.42 |
| SBPa (mmHg) | 126.38 ± 9.22 | 138.41 ± 13.96 | 134.64 ± 13.33 | 6.24 | <0.01 |
| BUN ( ± s, mmol/L) | 5.19 ± 1.35 | 5.71 ± 1.92 | 5.95 ± 1.44 | 1.23 | 0.33 |
| UA ( ± s, μmol/L) | 310.58 ± 72.61 | 344.00 ± 107.71 | 377.57 ± 72.01 | 2.59 | 0.08 |
| TC ( ± s, mmol/L) | 4.37 ± 0.86 | 4.38 ± 1.06 | 3.90 ± 0.88 | 1.39 | 0.26 |
| TG ( ± s, mmol/L) | 1.35 ± 0.73 | 1.51 ± 0.74 | 2.24 ± 3.57 | 1.19 | 0.31 |
| HDL ( ± s, mmol/L) | 1.41 ± 0.36 | 1.33 ± 0.44 | 1.01 ± 0.37 | 4.57 | <0.05 |
| LDL ( ± s, mmol/L) | 2.44 ± 0.66 | 2.46 ± 0.78 | 2.13 ± 0.53 | 1.21 | 0.31 |
| APO-A ( ± s, mmol/L) | 1.56 ± 0.36 | 1.52 ± 0.34 | 1.19 ± 0.32 | 5.59 | <0.01 |
| FSRP ( ± s, %) | 3.04 ± 1.30 | 8.70 ± 2.20 | 20.57 ± 4.40 | 200.22 | <0.01 |
Abbreviations: DM, diabetes mellitus; CVD, cardiovascular disease; AF, atrial fibrillation; LVH, left ventricular hypertrophy on ECG; SBP, systolic blood pressure; BUN, blood urea nitrogen; UA, uric acid; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; APO-A, apolipoprotein-A; FSRP, Framingham stroke risk profile. Note: “a” indicates the risk factors for Framingham stroke risk profile. The data are presented as means ± SD or number of cases (%).